期刊文献+

粪肠球菌噬菌体IME-EF3的分离及其治疗优势的发掘 被引量:4

Isolation of a novel Enterococcus faecalis phage IME-EF3 and its potential therapeutic advantages
下载PDF
导出
摘要 目的利用医院污水分离到临床耐药粪肠球菌的噬菌体IME-EF3,分析其生物学特性,发掘其治疗特性,为噬菌体制剂个体化治疗耐药粪肠球菌感染及利用噬菌体消除耐药粪肠球菌污染提供应用基础。方法利用医院污水,经污水富集法分离噬菌体,以粪肠球菌临床耐药分离株为宿主菌。经双层平板法确定噬菌斑形态及大小,纯化后测定其宿主谱范围、最佳感染复数(MOI)、一步生长曲线,并检测温度、紫外线照射对IME-EF3活性的影响。取适量噬菌体液,利用蛋白酶K俗DS法提取其基因组,对其进行酶切处理.确定其遗传物质的组成及形态。用酶切法进行了随机克隆,测序结果进行在线Blastx,并构建系统进化树分析与已知噬菌体的进化关系。结果成功分离到一株噬菌体斑.边缘清晰,斑体透明的裂解性粪肠球菌噬菌体IME-EF3热稳定性较好.对紫外线敏感。一步生长曲线显示IME-EF3的潜伏期为10~20min,呈爆发性增长,裂解量为75。其遗传物质为双链DNA,通过Blastx结果初步确定IME-EF3为尾病毒目,长尾噬菌体科。通过系统进化树可看出IME—EF3与其他噬菌体的亲缘关系较远。结论从医院废水成功分离到裂解性噬菌体IME-EF3,其爆发力强、潜伏期短、高裂解性、较好的热稳定性、与已知噬菌体远缘性等一系列的优良特点,为其噬菌体个体化治疗及与药物的联合使用提供了依据。 Objective To isolate bacteriophage and analyze its biological characteristics, and explore its potential in phage therapy against antibiotics resistant Enterococcus faecalis infections. Methods The bacteriophage IME-EF3 was isolated from the hospital sewage by using clinically isolated Enterococcus faeca!is as host. A double-layer agar plate method was used to determine the shape of plaque and the titer of phage preparations, the best multiplicity of infection(MOI), as well as the one-step growth curve. The heat and ultraviolet irradiation stability of IME-EF3 was analyzed by incubating the phage preparations at different temperatures and radiation durations. The phage genomic DNA was extracted using the method of K/SDS protease and characterized by nuclease digestion and agarose gel analysis. The DNA was then inserted into the cloning vector, and the sequenced result was blasted online. The phylogenetic tree of the major capsid proteins of IME-EF3 was formed by Neighbor- Joining method of MEGA5. Results Bacteriophage IME-EF3 was isolated successfully from hospital sewage, which was relatively heat-stable, but sensitive to ultraviolet irradiation. The one-step growth curve showed that IME-EF3 demonstrated explosive growth with an incubation period of 10 - 20 minutes and cracking capacity of 75. IME-EF3 genome was circular dsDNA. The Blastx sequencing results of a random fragment indicated that it belonged to the Siphoviridae. The relationship among IME-EF3 and other phages was distantly related. Conclusion It is demonstrated that the lyric bacteriophage IME-EF3 owns explosive growing strength with short incubation period, high cracking resistance and good thermal stability. The biological characterization of IME-EF3 provides useful information for the application of IME-EF3 as an alternative therapeutics to treat antibiotics-resistant Enterococcus faecalis infection.
出处 《生物医学工程与临床》 CAS 2014年第2期113-118,共6页 Biomedical Engineering and Clinical Medicine
基金 国家高技术研究发展计划(863计划)(2012AA022-003) 国家科技重大专项"十二五"实施计划(2013ZX10004-605 2013ZX10004-217 2013ZX10004-607 2011ZX10004-001) 国家科技重大专项"十二五"实施计划(2011ZX09401-023) 国家自然科学基金资助项目(81072350) 病原微生物生物安全国家重点实验室开放课题(SKLPBS1113)
关键词 粪肠球菌噬菌体 感染复数(MOI) 一步生长曲线 物理因素 DSDNA 长尾噬菌体科 进化树 Enterococcusfaecalis phage multiplicity of infection(MOI) one-step curve physical factors dsDNA Siphoviridae phylogenetic tree
  • 相关文献

参考文献19

  • 1Dejea C, Wick E, Sears CL. Bacterial oncogenesis in the colon [J]. Future Microbiology, 2013, 8(4): 445-460.
  • 2Mufioz-Atienza E, Gomez-Sala B, Arafijo C, et al. Antimicrobial activity, antibiotic susceptibility and virulence factors of Lactic Acid Bacteria of aquatic origin intended for use as probiotics in aquaculture[J]. BMC Microbiol, 2013, 13(15): 1-20.
  • 3Cebriana R, Banosa A, Valdivia E, et al. Characterization of fun- ctional, safety, and probiotie properties of Enterococcusfaecalis UGRAIO, a new AS-48-producer strain [J]. Food Microbiol, 2012, 30(1): 59-67.
  • 4Mohon JS, Tambyah PA, Ang BS, et al. The global spread of hea- hhcare-associated multidrug- resistant bacteria: a perspective from Asia[J]. Clin Infec Dis, 2013, 56(9): 1310-1318.
  • 5Bonilla N, Santiago T, Marcos P, et al. Enterophages, a group of phages infecting Enterococcusfaecalis, and their potential as a- lternate indicators of human faecal contamination[J]. Water Sci Technol, 2010, 61(2): 293-300.
  • 6王盛,童贻刚.噬菌体治疗研究进展[J].微生物学通报,2009,36(7):1019-1024. 被引量:34
  • 7Vieira A, Silva YJ, Cunha A, et al. Phage therapy to control mult- idrug-resistant Pseudomonas aeruginosa skin infections: in vi- tro and ex vivo experiments[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(11): 3241-3249.
  • 8Nakai T, Park SC. Bacteriophage therapy of infectious diseases in aquacuhure[J]. Res Microbiol, 2002, 153(1): 13-18.
  • 9McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudo- monas aeruginosa infection in a mouse burn wound model[J]. A- ntimicrob Agents Chemother, 2007, 51(6): 1934-1938.
  • 10Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience[J]. Arch Immunol Ther Exp(Warsz), 2000, 48(6): 547-551.

二级参考文献19

  • 1萨姆布鲁克 J,拉塞尔 D W.分子克隆实验指南[M].3版.林培堂,译.北京:科学出版社,2002.
  • 2Klare I, Witte W, Wendt C, et al. Vancomycin-resistant en-terococci(YRE): recent results and trends in development ofantibiotic resistance] [J]. Bundesgesundheitsblatt Gesundheits-forschung Gesundheitsschutz, 2012,55(11-12):1387-1400.
  • 3Karki S, Houston L, Land G, et al. Prevalence and risk fac-tors for VRE colonisation in a tertiary hospital in Melbourne,Australia: a cross sectional study[J]. Antimicrob Resist InfectControl, 2012,1(1):31.
  • 4Sulakvelidze A. Bacteriophage: a new journal for the mostubiquitous organisms on earth[J]. Bacteriophage, 2011,1(1):1-2.
  • 5Sulakvelidze A, Alavidze Z, Morris J J. Bacteriophage therapy[J]. Antimicrob Agents Chemother, 2001,45(3):649-659.
  • 6Clark J R, March J B. Bacteriophages and biotechnology: vac-cines, gene therapy and antibacterials[J]. Trends Biotechnol,2006,24(5):212-218.
  • 7Payne R J, Phil D, Jansen V A. Phage therapy: the peculiarkinetics of self-replicating pharmaceuticals[J]. Clin PharmacolTher,2000,68(3):225-230.
  • 8Thongkoom P, Kanjanahareutai S, Chantrakooptungool S, et al.Vancomycin-resistant enterococci(VRE) isolates isolated in Ra-javithi Hospital between 1999 and 2009[J]. J Med AssocThai, 2012,95(Suppl 3):S7-S15.
  • 9Matsuzaki S, Rashel M,Uchiyama J, et al. Bacteriophage ther-apy: a revitalized therapy against bacterial infectious diseases[J]. J Infect Chemother, 2005,11(5):211-219.
  • 10Abedon S T, Kuhl S J, Blasdel B G, et al. Phage treatmentof human infections[J]. Bacteriophage, 2011,1(2):66-85.

共引文献44

同被引文献15

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部